The project foresees the development of a base ready for oral use, mucoadhesive, able to solubilize Budesonide; this anti-inflammatory active ingredient has shown greater clinical efficacy for the treatment of eosinophilic esophagitis, a disease now considered rare, with a prevalent pediatric incidence.

The Wagner base is able to solubilize Budesonide (up to 8 mg/10 mL), increasing its bioavailability. It contains excipients that give it mucoadhesive properties and good palatability, increasing patient compliance.

Find out more, download the attachment.

Scarica allegato